<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587311</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2018-01503</org_study_id>
    <secondary_id>NCI-2018-01503</secondary_id>
    <secondary_id>PHL-098</secondary_id>
    <secondary_id>10150</secondary_id>
    <secondary_id>10150</secondary_id>
    <secondary_id>UM1CA186644</secondary_id>
    <nct_id>NCT03587311</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects of bevacizumab and anetumab ravtansine or&#xD;
      paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer&#xD;
      that does not respond to treatment (refractory). Bevacizumab is a monoclonal antibody that&#xD;
      may interfere with the ability of tumor cells to grow and spread. Anetumab ravtansine is a&#xD;
      drug that targets a protein in the body called mesothelin, which can be found in some&#xD;
      ovarian, pancreatic and other tumors. Chemotherapy drugs, such as paclitaxel, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. It is not yet known whether giving&#xD;
      bevacizumab and anetumab ravtansine or paclitaxel may work better in treating patients with&#xD;
      ovarian, fallopian tube, or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and tolerability of the combination of weekly anetumab ravtansine&#xD;
      (anetumab) and bi-weekly bevacizumab.&#xD;
&#xD;
      II. To determine whether the progression free survival (PFS) of the combination weekly&#xD;
      anetumab and bi-weekly bevacizumab is superior to weekly paclitaxel and bi-weekly&#xD;
      bevacizumab.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall response rate (ORR) according to Response Evaluation Criteria in&#xD;
      Solid Tumors (RECIST) version (v)1.1.&#xD;
&#xD;
      II. To evaluate the pharmacokinetic (PK) profiles of weekly anetumab in serum and in&#xD;
      peripheral blood mononuclear cells (PBMCs).&#xD;
&#xD;
      III. To evaluate anti-drug antibody (ADA) titers (only for patients receiving anetumab).&#xD;
&#xD;
      IV. To evaluate mononuclear phagocyte system (MPS) function, Fc-gamma receptors (FcgammaRs),&#xD;
      hormone and chemokine mediators.&#xD;
&#xD;
      V. To correlate the expression of CA125 (immunohistochemistry [IHC] &amp; serum) with mesothelin&#xD;
      expression in archival tissue and circulating megakaryocyte potentiating factor (MPF).&#xD;
&#xD;
      VI. To investigate blood-based angiome profiling as a potential biomarker. VII. To&#xD;
      characterize the molecular profile of archival tumor tissue using the Oncomine panel, and&#xD;
      explore whether genomic mutations such as BRCA1/2 and homologous repair deficiency status are&#xD;
      associated with clinical outcome.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To assess tumor tissue-based VEGF-dependent gene expression signature as a biomarker of&#xD;
      response.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      PHASE I: Patients receive anetumab ravtansine intravenously (IV) over 1 hour on days 1, 8,&#xD;
      15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PHASE II: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I: Patients receive anetumab ravtansine and bevacizumab as in Phase I.&#xD;
&#xD;
      GROUP II: Patients receive paclitaxel on days 1, 8, 15, and 22 and bevacizumab over 30-90&#xD;
      minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30-37 days and then every 8&#xD;
      weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Anticipated">October 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the time of treatment start assessed up to 1 year</time_frame>
    <description>PFS will be estimated using the Kaplan-Meier method and compared between groups with log rank test. Summary statistics will be provided, such as the median, 6-month and estimates, along with 95% confidence intervals. Plots will also be constructed which show the PFS estimate and 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate assessed using Response Evaluation Criteria in Solid Tumors</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Only one, single, final analysis is planned and statistical significance will be defined at the alpha = 0.05 level. All tests will be two-sided and 95% confidence levels will be constructed for outcomes of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Fallopian Tube Endometrioid Adenocarcinoma</condition>
  <condition>High Grade Fallopian Tube Serous Adenocarcinoma</condition>
  <condition>High Grade Ovarian Serous Adenocarcinoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Platinum-Resistant Fallopian Tube Carcinoma</condition>
  <condition>Platinum-Resistant Ovarian Carcinoma</condition>
  <condition>Platinum-Resistant Primary Peritoneal Carcinoma</condition>
  <condition>Primary Peritoneal High Grade Serous Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>GROUP I (anetumab ravtansine, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive anetumab ravtansine IV over 1 hour on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP II (paclitaxel, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anetumab Ravtansine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>GROUP I (anetumab ravtansine, bevacizumab)</arm_group_label>
    <other_name>BAY 94-9343</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>GROUP I (anetumab ravtansine, bevacizumab)</arm_group_label>
    <arm_group_label>GROUP II (paclitaxel, bevacizumab)</arm_group_label>
    <other_name>ABP 215</other_name>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Bevacizumab Biosimilar ABP 215</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar CT-P16</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar GB-222</other_name>
    <other_name>Bevacizumab Biosimilar HD204</other_name>
    <other_name>Bevacizumab Biosimilar HLX04</other_name>
    <other_name>Bevacizumab Biosimilar IBI305</other_name>
    <other_name>Bevacizumab Biosimilar LY01008</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar Mvasi</other_name>
    <other_name>Bevacizumab Biosimilar MYL-1402O</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>Bevacizumab Biosimilar RPH-001</other_name>
    <other_name>Bevacizumab Biosimilar SCT501</other_name>
    <other_name>Bevacizumab Biosimilar Zirabev</other_name>
    <other_name>Bevacizumab-awwb</other_name>
    <other_name>Bevacizumab-bvzr</other_name>
    <other_name>BP102</other_name>
    <other_name>BP102 Biosimilar</other_name>
    <other_name>HD204</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Mvasi</other_name>
    <other_name>MYL-1402O</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
    <other_name>Zirabev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>GROUP II (paclitaxel, bevacizumab)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed high grade serous or high&#xD;
             grade endometrioid ovarian, fallopian tube, primary peritoneal cancer&#xD;
&#xD;
          -  Patients must have platinum resistant (platinum-free interval &lt; 6 months) or platinum&#xD;
             refractory disease as per Gynecological Cancer Intergroup (GCIC) criteria&#xD;
&#xD;
          -  Patients must have radiologic evidence of disease progression&#xD;
&#xD;
          -  Criteria only for the randomized phase 2 part: patients must have measurable disease,&#xD;
             defined as at least one lesion that can be accurately measured in at least one&#xD;
             dimension (longest diameter to be recorded for non-nodal lesions and short axis for&#xD;
             nodal lesions) as &gt;= 20 mm with conventional techniques or as &gt;= 10 mm with spiral&#xD;
             computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by&#xD;
             clinical exam&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3 x 10^9/L&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets &gt;= 100 x 10^9/L&#xD;
&#xD;
          -  Total bilirubin =&lt; upper limit of normal (ULN) (except in Gilbert's syndrome)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =&lt;&#xD;
             2.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN OR creatinine clearance &gt;= 50 mL/min/1.73 m^2 for&#xD;
             patients with creatinine levels above 1.5 x institutional normal (using the Cockcroft&#xD;
             Gault formula)&#xD;
&#xD;
          -  Urine protein / creatinine ratio (UPCR) =&lt; 1&#xD;
&#xD;
          -  Ongoing prior toxicities related to previous treatments must be recovered to &lt; grade 2&#xD;
             at the time of registration (with the exception of alopecia, grade 2 peripheral&#xD;
             neuropathy or lymphopenia)&#xD;
&#xD;
          -  Criteria only for the randomized phase 2 part: mesothelin screen positive determined&#xD;
             from archival tumor tissue and to be performed centrally. MSLN-positive is defined as&#xD;
             &gt;= 30% of tumor cells with membrane staining intensities &gt;= 2+. If an archival tumor&#xD;
             specimen is unavailable, or unsuitable for mesothelin testing, a pre-treatment fresh&#xD;
             tumor biopsy is required&#xD;
&#xD;
               -  For the run-in-phase 1, patients will not be selected based on the mesothelin&#xD;
                  expression&#xD;
&#xD;
          -  Patients with known brain metastases are not excluded from this clinical trial.&#xD;
             Patients who received palliative radiation (for brain metastases) are eligible if they&#xD;
             have been asymptomatic for at least 4 weeks without use of maintenance steroid&#xD;
             therapy, and last received radiation at least 4 weeks prior to proposed start of&#xD;
             therapy&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
             Patients with Impaired Decision Making Capacity (IDMC) can have a Legally Authorized&#xD;
             Representative sign on their behalf. Documentation, such as a Power of Attorney, must&#xD;
             be presented in order for a substitute decision maker to be allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  History of severe allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to bevacizumab, anetumab ravtansine or paclitaxel&#xD;
&#xD;
          -  Patients receiving any medications or substances that are strong inhibitors or&#xD;
             inducers of CYP3A4 are ineligible. Because the lists of these agents are constantly&#xD;
             changing, it is important to regularly consult a frequently-updated list or medical&#xD;
             reference texts such as the Physicians' Desk Reference may also provide this&#xD;
             information. As part of the enrollment/informed consent procedures, the patient will&#xD;
             be counseled on the risk of interactions with other agents, and what to do if new&#xD;
             medications need to be prescribed or if the patient is considering a new&#xD;
             over-the-counter medicine or herbal product. Strong inhibitors and inducers of CYP3A4&#xD;
             are prohibited within 2 weeks before the start of and during treatment. Strong&#xD;
             inhibitors and inducers of CYP2C8 should be used with caution; the PI of the study is&#xD;
             to be consulted regarding their use&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because of the potential for teratogenic&#xD;
             or abortifacient effects. Because there is an unknown but potential risk for adverse&#xD;
             events in nursing infants secondary to treatment of the mother, breastfeeding should&#xD;
             be discontinued during the study and for at least 6 months after last dose of study&#xD;
             drugs. These potential risks may also apply to other agents used in this study. Women&#xD;
             of child-bearing potential who do not agree to use adequate contraceptive measures&#xD;
             during study therapy and for at least 6 months after the completion of study therapy&#xD;
             will be excluded. Should a patient become pregnant or suspect she is pregnant while&#xD;
             she is participating in this study, the patient should inform the treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Serious or non-healing wound, ulcer or bone fracture&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess&#xD;
             within 6 months prior to day 1&#xD;
&#xD;
          -  Invasive procedures defined as follows:&#xD;
&#xD;
               -  Major surgical procedure or significant traumatic injury within 28 days prior to&#xD;
                  day 1 therapy, or open biopsy within 7 days prior to day 1 therapy&#xD;
&#xD;
               -  Anticipation of need for major surgical procedures during the course of the study&#xD;
&#xD;
          -  Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or&#xD;
             recent peripheral arterial thrombosis) within 6 months prior to day 1&#xD;
&#xD;
          -  Patients with clinically significant cardiovascular disease are excluded&#xD;
&#xD;
               -  Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] &gt; 160&#xD;
                  mmHg and/or diastolic blood pressure [DBP] &gt; 90 mmHg despite antihypertensive&#xD;
                  medication)&#xD;
&#xD;
               -  History of cerebrovascular accident (CVA) within 6 months&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months&#xD;
&#xD;
               -  Serious and inadequately controlled cardiac arrhythmia&#xD;
&#xD;
               -  Significant vascular disease (e.g. aortic aneurysm, history of aortic dissection)&#xD;
&#xD;
               -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Patients with known hypersensitivity to Chinese hamster ovary cell products or other&#xD;
             recombinant human antibodies&#xD;
&#xD;
          -  Current symptom of keratitis or retinopathy at &gt;= grade 2&#xD;
&#xD;
          -  Resting electrocardiogram (ECG) with corrected QT interval by Fridericia (QTcF) &gt; 470&#xD;
             msec or family history of long QT syndrome&#xD;
&#xD;
          -  History of bowel obstruction within 28 days from proposed start of treatment&#xD;
&#xD;
          -  History or evidence of arterial thrombotic or hemorrhagic disorders within 3 months&#xD;
             before proposed start of treatment, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Prior use of weekly paclitaxel or bevacizumab in the platinum resistant (disease&#xD;
             progression within 6 months of platinum based chemotherapy)/refractory (disease&#xD;
             progression during or following the 3 months of the first line platinum based&#xD;
             chemotherapy) setting&#xD;
&#xD;
          -  Known active human immunodeficiency virus (HIV) or hepatitis B or C infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Lheureux</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network Princess Margaret Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Jill Tseng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>720-848-0650</phone>
    </contact>
    <investigator>
      <last_name>Bradley R. Corr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Coral Gables</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Matthew P. Schlumbrecht</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Matthew P. Schlumbrecht</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Matthew P. Schlumbrecht</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Matthew P. Schlumbrecht</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jing-Yi Chern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Dario R. Roque</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HaysMed University of Kansas Health System</name>
      <address>
        <city>Hays</city>
        <state>Kansas</state>
        <zip>67601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-623-5774</phone>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olathe Health Cancer Center</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-355-8000</phone>
      <email>Jeni.wakefield@olathehealth.org</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Via Christi - Pittsburg</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>620-235-7900</phone>
      <email>jennifer.jameson@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salina Regional Health Center</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-452-7038</phone>
      <email>mleepers@srhc.com</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Health System Saint Francis Campus</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-295-8000</phone>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea D. Jewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>313-576-9790</phone>
      <email>ctoadmin@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ira S. Winer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>313-576-9790</phone>
      <email>ctoadmin@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ira S. Winer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>732-235-7356</phone>
    </contact>
    <investigator>
      <last_name>Eugenia Girda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David M. O'Malley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Marta A. Crispens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>434-243-6303</phone>
      <email>uvacancertrials@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda R. Duska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>416-946-4501</phone>
      <email>clinical.trials@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Stephanie Lheureux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

